Intra-ophthalmic Artery Chemotherapy for Retinoblastoma

Matthew Wilson, Brian C. Tse, Rachel C. Brennan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The origin of intra-ophthalmic artery chemotherapy (SSIOAC) dates back to the 1950s. Cases of advanced intraocular retinoblastoma with (1) large multiple lesions still having enough normal retina so visual preservation was possible, (2) vitreous seeds, or (3) tumors refractory to other treatments presented a challenge for Reese and other early pioneers in the treatment of retinoblastoma, as they unfortunately still do today.

Original languageEnglish (US)
Title of host publicationClinical Ophthalmic Oncology
Subtitle of host publicationRetinoblastoma, Second Edition
PublisherSpringer Berlin Heidelberg
Pages129-136
Number of pages8
ISBN (Electronic)9783662434512
ISBN (Print)9783662434505
DOIs
StatePublished - Jan 1 2015

Fingerprint

Ophthalmic Artery
Retinoblastoma
Drug Therapy
Retina
Seeds
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Wilson, M., Tse, B. C., & Brennan, R. C. (2015). Intra-ophthalmic Artery Chemotherapy for Retinoblastoma. In Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition (pp. 129-136). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-662-43451-2_12

Intra-ophthalmic Artery Chemotherapy for Retinoblastoma. / Wilson, Matthew; Tse, Brian C.; Brennan, Rachel C.

Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition. Springer Berlin Heidelberg, 2015. p. 129-136.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wilson, M, Tse, BC & Brennan, RC 2015, Intra-ophthalmic Artery Chemotherapy for Retinoblastoma. in Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition. Springer Berlin Heidelberg, pp. 129-136. https://doi.org/10.1007/978-3-662-43451-2_12
Wilson M, Tse BC, Brennan RC. Intra-ophthalmic Artery Chemotherapy for Retinoblastoma. In Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition. Springer Berlin Heidelberg. 2015. p. 129-136 https://doi.org/10.1007/978-3-662-43451-2_12
Wilson, Matthew ; Tse, Brian C. ; Brennan, Rachel C. / Intra-ophthalmic Artery Chemotherapy for Retinoblastoma. Clinical Ophthalmic Oncology: Retinoblastoma, Second Edition. Springer Berlin Heidelberg, 2015. pp. 129-136
@inbook{72982536e1124a99854774a88476cf7b,
title = "Intra-ophthalmic Artery Chemotherapy for Retinoblastoma",
abstract = "The origin of intra-ophthalmic artery chemotherapy (SSIOAC) dates back to the 1950s. Cases of advanced intraocular retinoblastoma with (1) large multiple lesions still having enough normal retina so visual preservation was possible, (2) vitreous seeds, or (3) tumors refractory to other treatments presented a challenge for Reese and other early pioneers in the treatment of retinoblastoma, as they unfortunately still do today.",
author = "Matthew Wilson and Tse, {Brian C.} and Brennan, {Rachel C.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-3-662-43451-2_12",
language = "English (US)",
isbn = "9783662434505",
pages = "129--136",
booktitle = "Clinical Ophthalmic Oncology",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Intra-ophthalmic Artery Chemotherapy for Retinoblastoma

AU - Wilson, Matthew

AU - Tse, Brian C.

AU - Brennan, Rachel C.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The origin of intra-ophthalmic artery chemotherapy (SSIOAC) dates back to the 1950s. Cases of advanced intraocular retinoblastoma with (1) large multiple lesions still having enough normal retina so visual preservation was possible, (2) vitreous seeds, or (3) tumors refractory to other treatments presented a challenge for Reese and other early pioneers in the treatment of retinoblastoma, as they unfortunately still do today.

AB - The origin of intra-ophthalmic artery chemotherapy (SSIOAC) dates back to the 1950s. Cases of advanced intraocular retinoblastoma with (1) large multiple lesions still having enough normal retina so visual preservation was possible, (2) vitreous seeds, or (3) tumors refractory to other treatments presented a challenge for Reese and other early pioneers in the treatment of retinoblastoma, as they unfortunately still do today.

UR - http://www.scopus.com/inward/record.url?scp=84956712039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956712039&partnerID=8YFLogxK

U2 - 10.1007/978-3-662-43451-2_12

DO - 10.1007/978-3-662-43451-2_12

M3 - Chapter

SN - 9783662434505

SP - 129

EP - 136

BT - Clinical Ophthalmic Oncology

PB - Springer Berlin Heidelberg

ER -